March 30th 2023
A team of researchers at Buck Institute, working with Google Health and Zuckerberg San Francisco General Hospital, are studying the eye as a window into human aging.
Iveric Bio releases data in geographic atrophy from avacincaptad pegol GATHER trials
March 9th 2023According to the company, post-hoc time-to-event analysis signals up to 59% risk reduction in rate of vision loss compared to sham treatment at 12 months. The analysis will be presented at the ARVO Annual Meeting from April 23-27 in New Orleans.
Anti-properdin antibody demonstrates efficacy in a primate model of wet-AMD and dry-AMD
March 6th 2023The company’s therapeutic is a single therapy for multiple forms of age-related macular degeneration. NM3086 is a highly potent alternative pathway (AP) blocker that does not affect the classical pathway.
APAO 2023: Looking at anatomic outcomes in matched comparison: TENAYA and LUCERNE data
February 23rd 2023Greater anatomic improvements (central subfield thickness reduction, proportion with absence of subretinal fluid and intraretinal fluid) were seen with faricimab versus aflibercept during the matched dosing period (week 4, week 8, and week 12).
Angiogenesis 2023: The mystery of geographic atrophy shifts with data
February 10th 2023In a presentation at the 2023 Angiogenesis, Exudation, and Degeneration program, Usha Chakravarthy, PhD, FRCOphth, CBE, presented data from the trial of lampalizumab, which is peeling back some of the mystery shrouding geographic atrophy.
Angiogenesis 2023: Using ophthalmic artery angioplasty to treat AMD
February 10th 2023In a presentation at Bascom Palmer’s 2023 Angiogenesis, Exudation, and Degeneration conference in Miami, Pedro Lylyk, MD, said ophthalmic artery angioplasty could prove to be a treatment option for patients diagnosed with age-related macular degeneration.
Researchers find COVID impacts depth perception
December 23rd 2022The study, co-led by Griffith University’s Menzies Health Institute and South Korea’s Center for Convergent Research for Emerging Virus Infection, Korea Research Institute of Chemical Technology, aims to understand how SARS-CoV-2 affects the eyes and whether it could serve as a virus infection route.
Aviceda clears key IND toxicity hurdle with positive safety profile in non-human primates
December 8th 2022The results represent a major step towards first in-human clinical studies for this program - the first potential therapy for patients with geographic atrophy secondary to AMD that addresses the underlying causes of the disease.
Ranibizumab recall: Genentech recalls ocular implant in the US
October 18th 2022The company noted that testing of a commercial supply of the implants, which included exposing them to multiple punctures with a needle, found they did not meet their standards. The company has notified the FDA, and is working with the agency on the recall process.